✦ LIBER ✦

Predicting HBEAG loss by HBV DNA early kinetics and HBV genotype during treatment of HBEAG+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV)

✍ Scribed by A.U. Neumann; Y. Havlin; T. Ronen; M. Tsiang; M. Wulfsohn; C. Brosgart; J. Fry; C. Westland; S. Xiong; C.S. Gibbs

Book ID: 118566042
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 148 KB
Volume: 38
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(03)80486-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

36 Incidence and predictors of emergence

36 Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Correlation of the occurrence of YMDD mu

Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment

✍ Feng Wu; Min-Jin Wu; Xiao-Lin Zhuge; Shao-Ming Zhu; Biao Zhu 📂 Article 📅 2012 🏛 Zhejiang University School of Medicine, China 🌐 English ⚖ 111 KB

Prediction of response to entecavir ther

Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels

✍ J. W. Shin; S. W. Jung; B. R. Park; C. J. Kim; J. B. Eum; B. G. Kim; I. D. Jeong 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

Prediction of the response to peg-interf

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

✍ Bettina E. Hansen; Erik H.C.J. Buster; Ewout W. Steyerberg; Emmanuel Lesaffre; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to d

OL-026 Kinetics of interleukin-18 and HB

OL-026 Kinetics of interleukin-18 and HBV DNA during IFN-therapy induced and spontaneous anti-HBeAg seroconversion in patients with chronic hepatitis B

✍ Staffan Sylvan; Ulla Hellstrom 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Antiviral activity of 48 weeks of emtric

Antiviral activity of 48 weeks of emtricitabine (FTC) treatment in patients with HBeAg negative/HBV DNA positive chronic hepatitis B (CHB): Chia Wang, Larry Corey, Univ of Washington, Seattle, WA; Nancy Leung, Prince of Wales Hospital and Chinese Univ of Hong Kong; Shatin Hong Kong; Robert G Gish, CA Pacific Medical Ctr, San Francisco, CA; Amy Rigney, Lei Fang, Elsa Mondou, John Dillberger, Triangle Pharmaceuticals, Durham, NC

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB